BRL 28500

Known as: BRL-28500 
 
National Institutes of Health

Topic mentions per year

Topic mentions per year

1984-1987
02419841987

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
1987
1987
Clinical studies were conducted on BRL 28500 (a formulation containing 15 parts ticarcillin plus 1 part clavulanic acid). BRL… (More)
Is this relevant?
1987
1987
Clinical studies have been conducted on BRL 28500 (a formulation containing 15 parts ticarcillin (TIPC) plus 1 part clavulanic… (More)
Is this relevant?
1987
1987
Pharmacokinetics of the novel combination of ticarcillin with the beta-lactamase inhibitor clavulanic acid (BRL 28500, Timentin… (More)
Is this relevant?
1987
1987
Clavulanic acid/ticarcillin (BRL 28500) was administered to 36 patients with severe infections accompanying various hematological… (More)
Is this relevant?
1984
1984
A study was carried out to investigate the in vitro susceptibility of 211 clinical isolates of ticarcillin resistant (MICs… (More)
Is this relevant?